EISAI CO LTD

Explore how Eisai’s 5‑year Clarity AD data and real‑world LEADER results validate lecanemab’s sustained efficacy, safety and global market potential for early Alzheimer’s.

Explore how Eisai’s lecanemab drives Alzheimer’s therapy growth with real‑world data, subcutaneous dosing, and value‑based reimbursement, boosting global sales and market share.

Discover how Eisai’s LENVIMA® combinations are reshaping renal cell and endometrial cancer treatment—latest ESMO data, partnership highlights, and patient‑focused insights.

Newron’s FDA clinical hold on its US ENIGMA‑TRS 2 trial for the ion‑channel modulator evenamide underscores the agency’s arrhythmia concerns while the company reviews extensive ECG data and plans enhanced cardiac monitoring.